Search

Displaying results 3921 - 3930 of 8412 in total
  1. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses.

  2. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. … granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due

  3. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

  4. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.

    Synonyms: 7-D-MANDELAMIDO-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-3-CEPHEM-4-CARBOXYLIC ACID
  5. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

  6. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile.

  7. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. … general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Sarracenia Purpurea

    go.drugbank.com/drugs/DB13965
    ApprovedWithdrawn

    It was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509]. … Cytoprotection in an in vitro model of diabetic neuropathy has also been studied. However, the use of Sarracenia Purpurea extracts in the clinical setting are limited.

    Products: P-Bloc
  9. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Squalene

    go.drugbank.com/drugs/DB11460
    ApprovedInvestigationalVet approvedWithdrawn

    Squalene is investigated as an adjunctive cancer therapy.